Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785641 | 0.91 | MMP9 (0.44) | THRBOPRM1OPRD1OPRK1MMP1 | |
| SCHEMBL6783449 | 0.85 | KCNH2 (0.43) | THRBOPRM1OPRD1OPRK1MMP1 | |
| Hydrochloric Acid SCHEMBL6785113 | 0.84 | KCNH2 (0.45) | THRBOPRM1OPRD1OPRK1MMP1 | |
| SCHEMBL6905985 | 0.80 | MMP9 (0.43) | THRBOPRM1OPRD1OPRK1MMP1 | |
| SCHEMBL6780276 | 0.80 | KCNH2 (0.43) | THRBOPRM1OPRD1OPRK1MMP1 | |
| Hydrochloric Acid SCHEMBL6779775 | 0.80 | KCNH2 (0.44) | THRBOPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL6895994 | 0.78 | MMP1 (0.49) | MMP1MMP9MMP13ADAM17 | |
| SCHEMBL6783010 | 0.78 | MEN1 (0.40) | — | |
| SCHEMBL6783537 | 0.77 | KCNH2 (0.45) | THRBOPRM1OPRD1OPRK1MMP1 | |
| Hydrochloric Acid SCHEMBL6784418 | 0.76 | KCNH2 (0.47) | THRBOPRM1OPRD1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710060-B2 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-1182192-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | SCN5A, RYR2, SCN1B | THRB 825/4885OPRM1 366/4885OPRD1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.